Abstract:Background In our recently published working definition, we proposed that disease modification in systemic lupus erythematosus (SLE) requires ‘minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression’.[1] Objectives To apply the proposed non-renal disease modification criteria to SLE treatments. Methods Based on a review of a selection of clinical trial (n=31) and observational (n=42) data publications for 16 SLE medications across different treatment classes and, the authors’ clinical experience, we evaluated their disease modification potential per the non-renal disease activity and organ damage criteria at three time points (Table 1).[1] Results Nine of the 16 SLE treatments met at least one disease modification criterion across all time points (Table 1). Hydroxychloroquine improved overall survival at >5 years, suggesting long-term disease modification, but with data per specific criteria lacking.[2] Belimumab met two of the three disease modification criteria at the first two time points, but was the only treatment to meet criteria at >5 years based on the current literature. While steroids unambiguously decrease disease activity at early timepoints, at doses higher than 7.5 mg/day the negative impact on damage accrual might hamper their disease modification potential >5 years. Conclusion This is the first attempt to determine which of the currently used treatments in patients with SLE fulfil the disease modification criteria at different time points. Belimumab and hydroxychloroquine showed evidence of disease modification up to and beyond 5 years; evidence for many other SLE therapies was incomplete, particularly at >5 years of follow up. The use of multiple agents, differences in study designs, patient populations, and definitions of treatment response pose challenges in categorising treatments as disease modifiers. Future studies will evaluate the minimum number of criteria required to designate disease modification at each of the three time points so that disease modification can be considered in the care of patients with SLE and in SLE trial design. References [1]van Vollenhoven R et al. Lupus Sci Med 2022;9(1):e000634 [2]Ruiz-Irastorza G et al. Lupus 2006;15:577–83 Acknowledgements This review was funded by GSK. Medical writing support was provided by Casmira Brazaitis, PhD, and Cristina Teles, PhD, Fishawack Indicia Ltd, UK, part of Fishawack Health, and Hannah Jedrey, PhD, and Meer Basharat, PhD, of TVF Communications Ltd, UK, and was funded by GSK. Disclosure of Interests Anca Askanase Consultant of: AbbVie, Amgen, AstraZeneca, Aurinia, BMS, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, Pfizer and UCB, Richard Furie Speakers bureau: AstraZeneca, Genentech/Roche, Consultant of: GSK, Aurinia, AstraZeneca, BMS, Genentech/Roche, Grant/research support from: GSK, Aurinia, AstraZeneca, BMS, Genentech/Roche, Maria Dall’Era Consultant of: GSK, AstraZeneca, Aurinia, Pfizer, Janssen, Andrew Bomback Consultant of: Alexion, Principio, Calliditas, Aurinia, Catalyst, Travere, GSK, Visterra, Silence, Novo Nordisk, Otsuka, ChemoCentryx, Novartis, Andreas Schwarting Speakers bureau: GSK, AstraZeneca, Pfizer, Novartis, Roche, Janssen, Boehringer Ingelheim, Grant/research support from: GSK, Pfizer, AbbVie, Roche, Novartis, AstraZeneca, Ming-hui Zhao Consultant of: GSK, AstraZeneca, Novartis, Kira, Ian N. Bruce Speakers bureau: GSK, AstraZeneca, UCB, Consultant of: GSK, UCB, Eli Lilly, BMS, Merck Serono, Aurinia, IL-TOO, Grant/research support from: National Institute for Health Research (NIHR), GSK, Genzyme/Sanofi, MUNTHER KHAMASHTA Shareholder of: GSK, Employee of: GSK, Bernard Rubin Shareholder of: GSK, Employee of: GSK, Angela Carroll Shareholder of: GSK, Employee of: GSK, Mark Daniels Shareholder of: GSK, Employee of: GSK, Roger Levy Shareholder of: GSK, Employee of: GSK, Ronald van Vollenhoven Speakers bureau: AbbVie, Galapagos, GSK, Janssen, Pfizer, UCB, Roche, Consultant of: AbbVie, AstraZeneca, Biogen, Biotest, BMS, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB, Vielabio, Grant/research support from: Pfizer, Roche, Murray B Urowitz Speakers bureau: GSK, AstraZeneca, Consultant of: GSK, AstraZeneca, Grant/research support from: GSK.

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

Participant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project

Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis

Assessing recruitment and retention strategies in clinical trials for inequitable populations in systemic lupus erythematosus: A cross-sectional analysis

Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study

OP0246 ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE

FRI0419 the Epidemiology of Biopsy-Proven Lupus Nephritis: A Systematic Review and Meta-Analysis

The immune cell landscape in kidneys of patients with lupus nephritis

Lupus Low Disease Activity State As a Treatment Endpoint for Systemic Lupus Erythematosus: a Prospective Validation Study

Long-lasting severe knee pain in a SLE patient after renal transplantation: what is the reason? A case report and literature review

Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews

Acute Kidney Injury in Chinese Patients with Lupus Nephritis: A Large Cohort Study from A Single Center

A Systematic Review And Meta-Analysis Of Prevalence Of Biopsy-Proven Lupus Nephritis

Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)

APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS FROM THE PUBLISHED LITERATURE

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis